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Summary
 
Variable (V) region gene replacement was recently implicated in B cell repertoire diversifica-
tion, but the contribution of this mechanism to antibody responses is still unknown. To inves-
tigate the role of V gene replacements in the generation of antigen-specific antibodies, we ana-
lyzed antiviral immunoglobulin responses of “quasimonoclonal” (QM) mice. The B cells of
QM mice are genetically committed to exclusively express the anti-(4-hydroxy-3-nitrophenyl)
acetyl specificity. However, 
 
z
 
20% of the peripheral B cells of QM mice undergo secondary
rearrangements and thereby potentially acquire new specificities. QM mice infected with vesic-
ular stomatitis virus (VSV), lymphocytic choriomeningitis virus, or poliovirus mounted virus-
specific neutralizing antibody responses. In general, kinetics of the antiviral immunoglobulin
responses were delayed in QM mice; however, titers similar to control animals were eventually
produced that were sufficient to protect against VSV-induced lethal disease. VSV neutralizing
single-chain Fv fragments isolated from phage display libraries constructed from QM mice
showed V
 
H
 
 gene replacements and extensive hypermutation. Thus, our data demonstrate that
secondary rearrangements and hypermutation can generate sufficient B cell diversity in QM
mice to mount protective antiviral antibody responses, suggesting that these mechanisms might
also contribute to the diversification of the B cell repertoire of normal mice.
Key words: B cell gene rearrangement • vesicular stomatitis virus • mutation • viral antibodies • 
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T
 
he immune system of vertebrates has evolved complex
mechanisms to generate sufficient lymphocyte recep-
tor diversity to protect the organism against a wide range
of pathogens. Ab diversity is the result of several distinct
mechanisms, the major one being the rearrangement of
V(D)J gene segments to generate the coding sequences of
the V regions of the heavy and light chains of a functional
Ab molecule (1). Secondary rearrangements have mostly
been implicated in the elimination of autoreactive Abs in a
process called receptor editing (2–9). However, recent ex-
periments have suggested a role of receptor editing in the
generation of peripheral B cell diversity (8, 10–13). Despite
these observations, the actual contribution of secondary re-
arrangements to the shaping of the primary B cell reper-
toire is unclear because these rearrangements are often in-
distinguishable from the canonical V(D)J rearrangements.
Fortunately, gene-targeted mice expressing a very limited
B cell repertoire have been generated, one of which is the
“quasimonoclonal” (QM)
 
1
 
 mouse (14), which should allow
assessment of the role of V
 
H
 
 gene replacement in the gen-
eration of protective antiviral Ig responses.
The QM mouse was generated by gene-targeted replace-
ment of the endogenous J
 
H
 
 elements by the rearranged
17.2.25 V
 
H
 
(D)J
 
H
 
 region isolated from a (4-hydroxy-3-nitro-
phenyl) acetyl (NP)-specific hybridoma, whereas the other al-
lele was rendered nonfunctional by the targeted deletion of all
J
 
H
 
 segments. In addition, QM mice have no functional 
 
k
 
 light
chain allele; therefore, the transgenic heavy chain can only pair
with endogenously rearranged 
 
l
 
 chains. When paired with a 
 
l
 
light chain, the targeted heavy chain allows binding to NP-
 
1
 
Abbreviations used in this paper:
 
 LCMV, lymphocytic choriomeningitis vi-
rus; NP, (4-hydroxy-3-nitrophenyl) acetyl; PEG, polyethylene glycol;
PV, poliovirus; QM, “quasimonoclonal”; VSV, vesicular stomatitis virus;
VSV-IND, VSV Indiana serotype; VSV-G, VSV glycoprotein; scFv, sin-
gle-chain Fv. 
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hapten, rendering the QM primary B cell repertoire theoreti-
cally monospecific. However, despite this genetic predisposi-
tion, 20% of the peripheral B cells of QM mice do not bind
NP (15). In the absence of immunization, V
 
H
 
 gene replace-
ment intermediates were observed in bone marrow and
splenic B cells of QM mice, and recombinase-activating
gene (RAG)-1 transcripts were detected in the spleen (16).
To assess the extent of diversification generated through sec-
ondary rearrangements, we infected QM mice with different
viruses and monitored their specific antiviral responses. Our
results show that V
 
H
 
 replacements together with hypermuta-
tion can generate protective antiviral Ab specificities in QM
mice and indicate that both mechanisms could contribute to
diversify the B cell repertoire of normal mice.
 
Materials and Methods
 
Mice and Viruses.
 
The generation of the QM mouse has been
previously described (14). C57BL/6 mice were obtained from
the breeding colony of the Institut für Labortierkunde, Faculty of
Veterinary Medicine, University Zürich-Irchel, Zürich, Switzer-
land. Experiments were carried out with age- and sex-matched
animals kept under specific pathogen–free conditions. All animals
were 8–16 wk old unless indicated otherwise.
VSV-IND (vesicular stomatitis virus Indiana serotype; Mudd-
Summers isolate) was originally obtained from D. Kolakofsky
(University of Geneva, Switzerland), and was grown on BHK cells
in MEM with 5% FCS to virus stocks containing 10
 
9
 
 PFU/ml. Po-
liovirus (PV) stock solutions of serotypes I, II, and III were ob-
tained from the Swiss Serum and Vaccine Institute (Bern, Switzer-
land). Lymphocytic choriomeningitis virus (LCMV)-WE was
originally provided by F. Lehmann-Grube (Heinrich Pette Institut
für Experimentelle Virologie und Immunologie, University of
Hamburg, Hamburg, Germany), and was grown on L-929 cells for
48 h in MEM with 5% FCS after infection with an initial multi-
plicity of infection (moi) of 0.01.
 
Immunizations.
 
Mice were immunized intravenously on day
0 with a standard dose of 2 
 
3
 
 10
 
6
 
 PFU of VSV-IND or 200 PFU
of LCMV-WE as indicated. For PV experiments, 0.5 ml of PV
vaccine, Salk (minimal content [min.] 30 D-antigen U type 1,
min. 6 D-antigen U type 2, min. 24 D-antigen U type 3, phe-
noxyethanol; Poliomyelitis-Impstoff Berna, Swiss Serum and
Vaccine Institute) was injected intravenously on days 0 and 14.
Blood was collected at various time points as indicated.
 
VSV and PV Neutralization Assay.
 
Serial twofold dilutions of
serum samples (previously diluted 1:40) were mixed with equal vol-
umes of VSV or PV (PV serotype II was used) containing 500
PFU/ml, and the mixtures were incubated for 90 min at 37
 
8
 
C in an
atmosphere containing 5% CO
 
2
 
. 100 
 
m
 
l of the mixture was trans-
ferred onto Vero cell monolayers in 96-well plates and incubated
for 1 h at 37
 
8
 
C. Monolayers were overlaid with 100 
 
m
 
l of DMEM
containing 1% methylcellulose, incubated for 24 h (up to 48 h for
PV) at 37
 
8
 
C, then the overlay was removed and the monolayer was
fixed and stained with 0.5% crystal violet dissolved in 5% formalde-
hyde, 50% ethanol, 4.25% NaCl. The dilution reducing the number
of plaques by 50% was taken as titer (17). To determine IgG titers,
undiluted serum was treated with an equal volume of 0.1 M 2-ME
in MEM tissue culture medium for 1 h at room temperature.
 
LCMV Neutralization Assay: Infectious Focus Reduction Assay.
 
LCMV neutralization in vitro was determined as described previ-
ously (18). In brief, serial 2-fold dilutions of 10-fold prediluted
 
sera were incubated with LCMV for 90 min at 37
 
8
 
C in a 96-well
plate. MC57G mouse fibroblasts were added, and incubated for 4 h
to allow cells to settle and be infected by nonneutralized virus;
cells were then overlaid with 1% methylcellulose in DMEM. Af-
ter 48 h, cell monolayers were fixed with 4% formalin and infec-
tious foci were detected by intracellular LCMV staining of in-
fected cells with the rat anti-LCMV mAb VL-4. For LCMV
neutralization by total Ig, sera were tested under nonreducing
conditions. For LCMV neutralization by IgG, sera were first re-
duced by addition of 2-ME (final concentration 0.05 M) for 60
min. All samples were heat inactivated at 56
 
8
 
C for 30 min to de-
stroy complement.
 
Detection of Abs by ELISA.
 
To detect LCMV nucleoprotein–
specific Abs, 96-well plates were coated overnight at 4
 
8
 
C with
recombinant baculovirus–derived LCMV nucleoprotein (19, 20),
washed three to five times with PBS 0.05%/Tween 20, and
blocked with 1% BSA in PBS for 2–3 h at room temperature.
Sera diluted in PBS containing 0.1% BSA were added and incu-
bated for 90 min. Horseradish peroxidase–labeled specific goat
anti–mouse IgG Ab (1:1,000; Zymed Laboratories) was added for
1 h, and the reaction was developed by addition of 0.4 mM
ABTS (Boehringer Mannheim), in NaH
 
2
 
PO
 
4
 
, pH 4.0, 0.01%
H
 
2
 
O
 
2
 
. The OD was read at 405 nm using a microplate reader
(model 3550; Bio-Rad Laboratories). Positive titers were defined
as 3 SD above the mean value of negative controls. To measure the
different IgG isotype-specific anti-VSV Abs, ELISA plates were
coated with 10 
 
m
 
g/ml of polyethylene glycol (PEG)-precipitated
VSV-IND, and the assay was performed as described above.
 
Phage Display Library Construction.
 
Phage display libraries were
constructed as described previously (21). In brief, mRNA was
isolated from 10
 
7
 
 spleen cells using the QuickPrep mRNA purifi-
cation kit (Amersham Pharmacia Biotech) and reverse transcribed
using random hexamer primers according to the manufacturer’s
instructions (first strand synthesis for RT-PCR; Amersham Life
Science). The V region of the heavy chain (V
 
H
 
) was amplified
using the VHback and VHfor mixes of degenerate primers, and
the light chain V region (V
 
L
 
) was amplified using the 
 
l
 
-specific
primers LB
 
l
 
 and LF
 
l
 
 as described previously (21). The V
 
H
 
 and
V
 
L
 
 PCR products were purified and assembled in a single-chain
Fv (scFv) configuration using splicing by overlap extension PCR.
The full-length scFv fragment product was gel-purified, digested
with SfiI, and ligated into the phage display vector pAK100 (gift
of Dr. Andreas Plückthun, University of Zürich-Irchel, Zürich,
Switzerland). The ligation mixes were electroporated into XL1-
Blue electrocompetent cells (Stratagene, Inc.) and plated. Colo-
nies were scraped off the plates, and the scFv displaying phages
were rescued by infection with the VCS-M13 helper phage
(Stratagene, Inc.). Phage particles were PEG precipitated twice
and resuspended in PBS. VSV-binding phages were selected by
panning using immunotubes (Maxisorp; Nunc, Inc.) coated with
100 
 
m
 
g/ml PEG-precipitated VSV-IND particles by overnight
incubation at room temperature. Tubes were blocked with 4%
dried skim milk powder in PBS and washed 20 times with PBS
containing 0.1% Tween and 20 times with PBS. Bound phages
were eluted with 0.1 M glycine/HCl, pH 2.2, for 10 min and
immediately neutralized with 2 M Tris/HCl, pH 8.5. Eluted
phages were used to infect XL1-Blue cells that were plated, res-
cued as described above, and subjected to another round of pan-
ning before isolated clones were analyzed by ELISA. Isolated col-
onies from the second round of panning were grown in 96-well
plates and rescued with VCS-M13 helper phage. After overnight
incubation, 100 
 
m
 
l of the phage-containing supernatant was
added to VSV-coated plates (10 
 
m
 
g/ml) and incubated for 90 
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min. The wells were washed five times with PBS containing
0.1% Tween, and peroxidase-labeled anti-M13 antiserum (Amer-
sham Pharmacia Biotech) was then added and the plates incu-
bated for another 90 min. The plates were again washed five
times with PBS/0.1% Tween, and the bound peroxidase was
revealed by incubation with 
 
O
 
-phenylenediamine (Sigma Chem-
ical Co.) and hydrogen peroxide. The reaction was stopped with
1 N HCl, and the absorbance was read at 490 nm using a Bio-
Rad 3550 microplate reader.
 
Results and Discussion
 
Induction of Neutralizing Abs against VSV-IND in QM
Mice.
 
VSV is a cytopathic RNA negative strand virus of
the 
 
Rhabdoviridae
 
 family closely related to rabies virus (22).
After VSV infection, virus-neutralizing Abs mediate pro-
tection against a progressive paralytic disease (23, 24). Most
VSV-IND–specific mAbs are directed against overlapping
subsites clustered within one major antigenic site of the
viral glycoprotein (25–27). The early IgM response (days
3–5) can be induced in the absence of T cell help (28, 29),
whereas the switch to IgG (days 6–8) is T cell help depen-
dent (30).
QM and C57BL/6 mice were immunized with 2 
 
3
 
 10
 
6
 
PFU of VSV-IND intravenously, and neutralizing serum
Abs were monitored for 150 d. VSV total Ig neutralizing
titers were measurable in QM mice 4 d after infection, but
these titers were 
 
z
 
30-fold lower than in C57BL/6 control
mice (Fig. 1 a). The switch to the IgG subclass was delayed
by 
 
z
 
6 d in QM mice: VSV-neutralizing IgG Abs appeared
 
z
 
12 d after infection, whereas in control mice they were
first detected at about day 6 (Fig. 1 a). About 40 d after in-
fection, total anti-VSV neutralizing Abs reached similar
levels in QM and control mice, and remained elevated for
the duration of the 150-d observation period (Fig. 1 a).
Similar kinetics were observed after infection with 10
 
2
 
 or
10
 
4
 
 PFU of VSV-IND (data not shown). Despite the de-
layed kinetics of Ab production, QM mice were able to
control the viral infection and survived. However, the
LD
 
50
 
 was decreased 10-fold from 2 
 
3 
 
10
 
8
 
 in C57BL/6
control mice to 2 
 
3
 
 10
 
7
 
 in QM mice (data not shown).
Determination of the isotypes of the VSV-specific IgG
Abs revealed that IgG2a was more abundant in infected
QM mice than in control mice (Fig. 1 b). In contrast, IgG1
titers were higher in the control animals than in QM mice,
while IgG2b and IgG3 Ab titers were approximately the
same (Fig. 1 b). Similarly to infected QM mice, naive QM
mice also show elevated IgG2a and IgG2b levels, which
may indicate a certain bias towards Th1 cell development
in QM mice (14).
The delayed kinetics of the VSV-neutralizing Ig re-
sponse in QM mice was not due to the absence of kappa
light chains because C
 
k
 
-deficient mice (31) mounted virtu-
ally normal anti-VSV Ig responses (data not shown). The
delayed kinetics observed in QM mice is likely to be attrib-
utable to the time required for the small number of anti-
VSV B cell precursors present in naive QM mice to be ac-
tivated or expanded and to produce sufficient serum Abs to
be detected in the neutralization assay. It has previously
been reported that the amount of NP-specific serum IgG1
decreased from 13.1% of total IgG1 in 4–5-wk-old QM
mice to 2.8% in 20–24-wk-old mice, which is consistent
with the idea that B cells with variant receptors are prefer-
entially expanded as QM mice age (15). This could lead to
increased numbers of VSV-specific B cell precursors and an
accelerated VSV-neutralizing Ab response in older mice.
To test this hypothesis, 9- and 56-wk-old QM mice were
infected with 2 
 
3
 
 10
 
6
 
 PFU of VSV-IND. The anti-VSV
neutralizing Ab response in both 9- and 56-wk-old QM
mice displayed similar kinetics, suggesting that there was no
significant increase in the number of VSV-specific B cell
precursors in QM mice older than 9 wk (Fig. 1 c).
 
Analysis of VSV-specific scFv Fragments Isolated from QM
Mice.
 
To analyze V region sequences of VSV-specific
neutralizing Abs generated in QM mice, phage display li-
Figure 1. QM mice mount VSV-specific Ig responses. Groups of three
QM and C57BL/6 mice were immunized with 2 3 106 PFU of VSV-
IND intravenously. Blood was taken at the indicated time points, sera
were separated and prediluted 40-fold, and the Ig responses were ana-
lyzed. (a) Kinetics of VSV-neutralizing Ab responses in QM and C57BL/6
mice. (b) Titration of the different VSV-specific Ig isotypes in infected
QM and C57BL/6 mice. Titers were defined as 3 SD above mean values
of negative controls. (c) Kinetics of VSV-neutralizing responses of 9- and
56-wk-old QM mice. C57BL/6 mice were used as controls. 
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braries were constructed from splenic mRNA isolated from
naive QM mice and from QM mice after primary and sec-
ondary VSV-IND infections. In a screening ELISA, 37% of
the phages isolated from the naive library and 
 
z
 
57% of the
phages isolated from QM spleens after primary or second-
ary VSV infections bound VSV. Thus, it can be concluded
from this result that VSV-specific B cells were present in
QM mice before infection. The serum of the mouse used
to generate the naive library was tested for the presence of
VSV-specific Abs and was found to be negative. In addi-
tion, it must be emphasized that mice kept in our facilities
for prolonged periods of time have been tested repetitively
during the last 10 yr, and in no circumstances have we
found the presence of VSV-IND–specific Abs, which
could indicate accidental spreading of virus. Individual
clones showing strong positive signals in the screening
ELISA were concentrated by PEG precipitation and tested
for their relative binding potential to VSV in a second
ELISA. As shown in Fig. 2 a, scFv-displaying phages
showed a specific dose-dependent binding to VSV-coated
plates. To identify clones specific for the viral glycoprotein
(VSV-G), binding of phages to VSV-infected EL4 cells ex-
pressing VSV-G on their surface was analyzed cytofluoro-
metrically. From 48 tested clones, 15 showed binding to
VSV-infected EL4 cells (data not shown). These 15 glyco-
protein-specific clones were tested in a VSV-neutralization
assay, which revealed that 12 out of 15 clones neutralized
viral infectivity in vitro. The neutralizing titers of six inde-
pendent scFv clones (see below) are shown in Fig. 2 b.
The V regions of the 12 VSV-neutralizing scFv Ab frag-
ments were sequenced and aligned to the 17.2.25 V
 
H
 
 se-
quence expressed in QM mice. From the 12 clones ana-
lyzed, 6 independent sequences were identified, 2 from
each of the three libraries (Fig. 2 c). Clones 0B1 and 0G6
were isolated from the naive library, clones 1A10 and 1E12
from the primary library, and clones 2F7 and 2H5 from the
secondary library. The other six clones were multiple iso-
lates of clone 0G6 (four copies) and of clone 1A10 (two
copies); such repeated isolation is often the consequence of
the amplification of binding clones during the panning pro-
cedure. All six independent clones used a V
 
L
 
 fragment be-
longing to the 
 
l
 
1 family. In addition, they all showed evi-
dence for V
 
H
 
 gene replacement. Instead of the original
17.2.25 V
 
H
 
 gene segment, all clones used a different V
 
H
 
gene segment belonging to the VH1 (J558) family that has
previously been shown to play a role in secondary and hy-
perimmune responses against VSV in BALB/c mice (32).
All six analyzed clones underwent secondary rearrange-
ments by recombining a rearranged V
 
H
 
D segment with the
D element of the rearranged V
 
H
 
DJ
 
H
 
 segment of the QM
mouse (Fig. 2 c). This type of V
 
H
 
D to V
 
H
 
DJ
 
H
 
 rearrange-
ment has previously been observed in naive QM mice in
the majority of idiotype-negative sorted B cells (14, 15).
However, unlike the events described here, a small propor-
tion of idiotype-negative B cells did show signs of canoni-
cal V
 
H
 
 to V
 
H
 
DJ
 
H
 
 secondary rearrangements (14, 15).
Therefore, it is possible that such V
 
H
 
D to V
 
H
 
DJ
 
H
 
 rear-
rangements are preferred to the canonical secondary rear-
rangements because they generate greater diversity by dras-
tically varying the length of CDR3, which might in turn
increase the chances of generating new specificities. It is
unclear whether the heptamer motif embedded at the 3
 
9
 
end of the V
 
H
 
 gene segment of the 17.2.25 V region and
most other V
 
H
 
 gene segments was involved in these rear-
Figure 2. Binding, neutralizing capacity,
and sequence analysis of VSV-specific scFv
fragments isolated from phage display librar-
ies. (a) Phage clones displaying VSV-specific
scFv fragments isolated from a naive QM
mouse library (0B1 and 0G6) and libraries
generated from QM mice after primary
(1A10 and 1E12) or secondary (2F7 and
2H5) infections were tested for their capacity
to bind VSV-coated plates in ELISA. (b)
VSV-neutralizing titers of PEG-precipitated
phage particles. (c) The nucleotide sequence
of six VSV-specific clones is compared with
the 17.2.25 transgene sequence (reference
16) shown in bold. Mutations in the DSP2.10
and JH4 segments are underlined. The re-
maining 39 sequence of the JH4 segments did
not contain somatic hypermutations. The se-
quences of the complete scFv fragments are
available from EMBL/GenBank/DDBJ un-
der accession nos. AF127092–AF127097. 
1795
 
López-Macías et al.
 
rangements because the recombination breakpoint cannot be
unambiguously determined. In addition, N regions flanking
the inserted D elements were present in all analyzed clones
(Fig. 2 c), which argues for the involvement of the normal
rearrangement machinery including terminal deoxynucleoti-
dyl transferase (TdT), which is expressed in bone marrow B
cells and has recently been shown to be also reexpressed in
germinal center B cells (13). Furthermore, the 6 VSV-spe-
cific clones sequenced showed extensive hypermutation in
the remaining DSP2.10 and JH4 segments of clone 17.2.25
with a high frequency of 3.8% (15 mutations in 393 bp cu-
mulated from the 6 scFv sequences). Interestingly, mutations
were present in clones isolated from the naive library, con-
firming the results obtained in B cells isolated from the pe-
ripheral blood of unimmunized QM mice that also showed a
high frequency of somatic mutations (14).
 
Induction of LCMV- and PV-specific Abs in QM Mice.
 
Since germline Abs can already efficiently neutralize VSV in-
fection in vitro and a relatively restricted B cell repertoire
can mount an efficient early anti-VSV response
 
 
 
(27), it is
possible that by chance the right V
 
H
 
/V
 
L 
 
pairing in QM mice
could give rise to VSV-specific but not other virus-specific
Abs. Therefore, in addition to the VSV-specific Ig response,
the responses of QM mice to LCMV and PV were analyzed.
LCMV is a noncytopathic ambisense RNA virus of the
 
Arenaviridae
 
 family for which the mouse is the natural host.
Acute LCMV infection is predominantly controlled by CTLs
in a perforin-dependent manner (33, 34). Early after infec-
tion, at about day 8, a strong Ab response specific for the
LCMV nucleoprotein is mounted (20) that does not exhibit
virus-neutralizing capacity (35, 36). Late after infection, be-
tween days 30 and 60, LCMV glycoprotein–specific neutral-
izing Abs develop (20, 37, 38) that have been shown to play
an important role in protection against reinfection (39–41).
QM and C57BL/6 mice were immunized intravenously
with 10
 
2
 
 PFU of LCMV-WE, and the LCMV nucleopro-
tein–specific ELISA Ab and the LCMV-neutralizing Ab re-
sponses were monitored. QM mice mounted a delayed
LCMV nucleoprotein–specific Ab response at about day 12
that was initially reduced by z10-fold in comparison with
control mice, but which eventually reached similar levels
by day 32 (Fig. 3 a).
Neutralizing Abs to LCMV normally appearing late after
infection (20, 37, 38) followed the same slow kinetics in
QM and control mice (Fig. 3 b). Low neutralizing Ab titers
were first detected after 30 d of infection, and by day 70 a
distinct neutralizing Ab response was measured in both
QM and C57BL/6 mice (Fig. 3 b). The long time period
required to mount a neutralizing response against LCMV
could well have permitted the generation of sufficient
LCMV-specific precursors to mount a neutralizing Ab re-
sponse comparable to control animals. On the other hand,
the reason for the long period of time needed to generate
LCMV-neutralizing Abs is not well understood and could
be dependent on factors other than low B cell precursor
frequency (e.g., immunopathology [42]).
PV is a cytopathic positive strand RNA virus of the Pi-
cornaviridae family. The viral surface contains four regularly
ordered proteins (VP1–4) against which neutralizing Abs
are directed (43). In BALB/c mice, PV induces an early T
cell–independent IgM response followed by a T cell–depen-
dent IgG response (44). Early after immunization with for-
malin-inactivated PV (Salk vaccine), total neutralizing Ig
titers in QM mice were similar to control animals (Fig. 3 c).
The IgG response was initially delayed, but 20 d after in-
fection titers reached the levels observed in C57BL/6 con-
trol mice. Interestingly, in the memory phase after 28 d of
infection, serum titers in QM mice showed a three- to
fourfold reduction compared with controls (Fig. 3 c). This
could reflect differences in the numbers or in the expansion
potential of the PV-specific B cell clones generated in QM
mice. In addition, the inactivated PV vaccine used in this
experiment might have provided a weaker stimulus for the
selection and expansion of PV-specific QM B cells.
Taken together, our experiments have shown that VH
replacement and hypermutation generated the VSV-spe-
cific immune response observed in QM mice and demon-
strated the surprisingly great diversification potential of the
Figure 3. QM mice mount neutralizing Ig responses against LCMV and
PV. Groups of three mice were immunized with 200 PFU of LCMV-WE or
0.5 ml of PV (Salk vaccine) intravenously. (a) LCMV nucleoprotein–specific
Ab titers were measured by ELISA. (b) LCMV-neutralizing Abs and (c)
PV-neutralizing Abs were measured as described in Materials and Methods.1796 Antiviral Immunoglobulin Responses in “Quasimonoclonal” Mice
QM B cell repertoire, establishing that this phenomenon is
not restricted to one particular viral antigen.
Where was VH replacement taking place in QM mice,
and what triggered it? The current model for the role of re-
ceptor editing in B cell development incorporates two dif-
ferent events (45). During the early phase of B cell devel-
opment in the bone marrow, editing is induced by the
interaction between a self-antigen and the receptor of a de-
veloping B cell (2–4). At a later phase, weak interaction be-
tween antigen and the B cell receptor of a mature periph-
eral B cell would induce editing, whereas strong binding
turns it off (12, 13). Evidence for the occurrence of VH re-
placement in both bone marrow and spleen of nonimmu-
nized QM mice was recently reported (16). However, a
slight accumulation of idiotype-negative cells in the spleen
compared with the bone marrow suggests that the spleen
might be a privilege site for ongoing secondary rearrange-
ment (16). In addition, a higher proportion of idiotype-
negative B cells was also observed in B cells isolated from
the peritoneum when compared with peripheral blood
(15). Thus, it would appear that there is a constant need for
diversification of the QM mouse B cell repertoire through-
out B cell development and in different tissues.
The molecular events involved in the induction of sec-
ondary rearrangements are still not clearly defined, but dif-
ferent triggering mechanisms could be envisaged. First, B
cells could have a certain intrinsic capacity to undergo re-
ceptor editing in an antigen-independent fashion through
help from T cells, cytokines, or other stimuli. Although
this scenario cannot be ruled out, there is enough evidence
supporting the notion that B cell receptor triggering is re-
quired for induction of secondary rearrangements both in
the bone marrow (7, 8) and in the periphery (10–12) to
make this unlikely. The B cell receptor in QM mice would
not be expected to bind any other antigen than NP with
high affinity. However, it could be argued that weak cross-
reactive interactions between NP-specific B cells and dif-
ferent antigens could induce V gene replacement and gen-
erate virus-specific B cells. Second, it was proposed that
environmental antigenic pressure could be the driving
force behind the diversification of the V gene repertoire of
naive QM mice (15). Recent data suggested that secondary
rearrangements in peritoneal B-1 cells might contribute to
the development of autoreactive Abs (46). In this study, the
authors proposed that frequent exposure of B-1 cells to
LPS may lower the threshold for activation of secondary
rearrangements resulting in a rapid shift in the Ab reper-
toire. In view of our findings, this mechanism could gener-
ate not only autoreactive B cells but also potentially useful
pathogen-specific Abs. On the other hand, de novo VH re-
placement could have been triggered by cross-reactive
binding of the NP-specific B cell receptor to the viral anti-
gens used in this study. Although viral antigens might play
a role in the expansion and maintenance of the virus-spe-
cific B cells in the infected mice, these interactions may be
excluded as initial triggering events because VSV-specific
scFv Abs were isolated from a phage display library con-
structed from a naive QM mouse. Therefore, virus-specific
clones were generated in QM mice even before the intro-
duction of viral antigens. In addition, nonimmunized QM
mice undergo frequent VH replacement (14, 15).
It is difficult to address the role of these events in the com-
plexity of a normal Ab response. However, new evidence is
emerging in favor of the frequent involvement of secondary
rearrangements during normal B cell development (47).
Moreover, sequence analysis of human heavy and light chain
V domains suggested that receptor editing occurs in human
peripheral B cells (48). Taken together with our results, these
experiments suggest that, together with hypermutation, sec-
ondary rearrangement could participate in the shaping of the
natural B cell repertoire. In conclusion, our data illustrate the
potential of VH gene replacements in the diversification of a
restricted repertoire and definitely show that this expanded
repertoire is functional.
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